ibrutinib
Ibrutinib is used to treat chronic lymphocytic leukemia Waldenström's macroglobulinemia, and as a second-line treatment for mantle cell lymphoma, marginal zone lymphoma, and chronic graft vs host disease. It is a small molecule drug. Reference standards of Ibrutinib API,and its pharmacopeial, non pharmacopeial impurities, and stable isotopes are listed below.
stdClass Object
(
[pname] => 1-(1-Nitrosopiperidin-3-yl)-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
[catalogue_number] => PA 09 0271021
[category_ids] => ,70,71,78,82,162,
[chemical_name] =>
[weight] => 415.46
[form] => C22H21N7O2
[cas] => 2256059-43-3
[pslug] => 2256059-43-3-1-1-nitrosopiperidin-3-yl-3-4-phenoxyphenyl-1h-pyrazolo-3-4-d-pyrimidin-4-amine-pa090271021
[latest_product] => 0
[linkproducts] => 0
[offers_id] =>
[offers_name] =>
[offers_status] =>
[offers_start_date] =>
[offers_end_date] =>
[pageview] =>
[offers_slug] =>
[offers_product_id] =>
[offers_product_code] =>
[offers_master_id] =>
[offer_percentage] =>
[offers_product_main_cat] =>
)
1-(1-Nitrosopiperidin-3-yl)-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
Catalogue No.:PA 09 0271021
Molecular Formula : C22H21N7O2
Molecular Weight : 415.46
stdClass Object
(
[pname] => (R)-1-(1-Nitrosopiperidin-3-yl)-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
[catalogue_number] => PA 09 0271027
[category_ids] => ,79,80,81,78,162,
[chemical_name] =>
[weight] => 415.46
[form] => C22H21N7O2
[cas] => NA
[pslug] => r-1-1-nitrosopiperidin-3-yl-3-4-phenoxyphenyl-1h-pyrazolo-3-4-d-pyrimidin-4-amine-pa090271027
[latest_product] => 0
[linkproducts] => 0
[offers_id] =>
[offers_name] =>
[offers_status] =>
[offers_start_date] =>
[offers_end_date] =>
[pageview] =>
[offers_slug] =>
[offers_product_id] =>
[offers_product_code] =>
[offers_master_id] =>
[offer_percentage] =>
[offers_product_main_cat] =>
)
(R)-1-(1-Nitrosopiperidin-3-yl)-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
Catalogue No.:PA 09 0271027
Molecular Formula : C22H21N7O2
Molecular Weight : 415.46
